Researchers have discovered and validated a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive impairment or Alzheimer’s disease within three years.
Described in the April issue of Nature Medicine, the study heralds the potential for developing treatment strategies for Alzheimer’s at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms. It is the first known published report of blood-based biomarkers for preclinical Alzheimer’s.
The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible.
“Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder,” says the study’s corresponding author Howard J. Federoff, MD, PhD, professor of neurology and executive vice president for health sciences at Georgetown University Medical Center.
There is no cure or effective treatment for Alzheimer’s. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.
Federoff explains there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.
“The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention,” Federoff says. “Biomarkers such as ours that define this asymptomatic period are critical for successful development and application of these therapeutics.”
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Predicting Alzheimer's-like memory loss before it strikeson December 2, 2019 at 8:38 am
For someone with Alzheimer's disease, there's no turning back the clock. By the time memory loss and other worrisome signs appear, cognitive decline has already begun. "Being able to predict deficits ...
- Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’son December 2, 2019 at 8:29 am
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in ...
- Biogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Sayson December 2, 2019 at 7:31 am
On Monday morning, he stuck it into Biogen. In a scathing note, Skorney laid out the case that Biogen’s experimental Alzheimer’s drug aducanumab won’t get approved by the Food and Drug Administration.
- CorTechs Labs Presents Findings Regarding Alzheimer’s Disease at the Radiological Society of North America’s (RSNA) 2019 Annual Meetingon December 2, 2019 at 7:05 am
In addition to technical exhibits on both the main floor and AI Showcase, the company will present their findings from a recent study titled: “Determining Brain Age Using Machine Learning Combined ...
- Grifols to present latest Alzheimer's clinical trial resultson December 2, 2019 at 6:28 am
BARCELONA, Spain, Dec. 2, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, ...
- Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conferenceon December 2, 2019 at 6:18 am
WOODCLIFF LAKE, N.J., Dec. 2, 2019 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company's rich dementia pipeline, including ...
- INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Studyon December 2, 2019 at 5:00 am
LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, ...
- BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conferenceon December 1, 2019 at 11:41 pm
STOCKHOLM, Dec. 2, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12 th Clinical Trials on Alzheimer's ...
- The Unending Indignities of Alzheimer’son December 1, 2019 at 12:00 pm
I remember my father like that — young, and in love with his children, and their mother, and our little slice of the universe. He got a diagnosis of Alzheimer’s in 2016. This year, his doctor told us ...
- Up Close: The battle against Alzheimer's diseaseon December 1, 2019 at 9:01 am
NEW YORK (WABC) -- Nearly 6 million Americans suffer from what is generally called Alzheimer's, and it is only getting worse. This week on Up Close, actor David Hyde Pierce talks about the battle his ...
via Bing News